Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Trial Profile

A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efpeglenatide (Primary) ; Liraglutide
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EXCEED; EXCEED 203
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 18 Jul 2019 Safety and efficacy results published in the Diabetes Care.
    • 11 Jun 2019 Results of post-hoc sub analysis stratified by baseline characteristics, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 11 Jun 2019 Subanalysis results from EXCEED 203 study were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top